Idiopathic short stature
Conditions
Interventions
trial group:NA
Sponsors
Huangshi Maternal and Child Health Hospital
Eligibility
Sex/Gender
All
Age
3 Years to 14 Years
Inclusion criteria
Inclusion criteria: 1) Symmetric short stature. The height falls behind the 3rd percentile (P3, -1.88 SD) or 2 standard deviations (SD) of the growth curve of normal children of the same age and gender; 2) The results of any drug stimulation test indicate that the GH peak value is greater than 10ug/l; 3) Slow growth, growth rate<5cm/year; 4) Normal intelligence, mental state, and consciousness; 5) Birth length, weight, and body proportion are all normal, and no evidence of systemic, endocrine, nutritional, chromosomal abnormalities or genetic variations has been found; 6) After sufficient communication, the patient's family members were informed and agreed to use polyethylene glycol recombinant human growth hormone injection for treatment, and signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1) Excluding other primary growth disorders that affect growth (such as genetic syndrome) and secondary growth disorders, including various diseases related to environment, hormones, nutrition, and/or systemic organic diseases, such as Cushing's syndrome, hypothyroidism, pseudohypoparathyroidism, growth hormone deficiency, bone/chondropathy, small for gestational age infants, chromosomal diseases, Turner syndrome, Noonan syndrome, etc; 2) Individuals who are allergic to polyethylene glycol recombinant human growth hormone injection (Jinsaizeng) and its excipients; 3) The patient has diseases and tumors that are not suitable for treatment with growth hormone, such as important organ dysfunction such as heart, liver, kidney, and other chronic diseases, or pituitary dysfunction, cerebrovascular diseases, etc; 4) Researchers believe that there are other situations where growth hormone therapy is not appropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 12 months after treatment, changes in height SDS and height SDS of subjects;12 months after treatment, the increase in height of the subjects; | — |
Secondary
| Measure | Time frame |
|---|---|
| Subject medication adherence during the study period;BMI and BMI SDS during the study period (3, 6, 9, and 12 months after treatment);Adverse drug reactions during the study period;Changes in height SDS and height SDS of subjects at 3, 6, and 9 months after treatment;After 3, 6, and 9 months of treatment, the increase in height of the subjects; | — |
Countries
China
Contacts
Public ContactJianhua LIU
Huangshi Maternal and Child Health Hospital
Outcome results
None listed